Endo Aims To Stabilize Generics Unit In 2021
Company Delivers Another Underwhelming Quarter
Endo will focus on restructuring initiatives and new launches in 2021 to stabilize its generics business, after the company reported a 20% drop in generics sales for the fourth quarter of 2020, with full-year sales down by more than a tenth.
